LABELS · e73179c2-1306-443c-a5ed-d2748e96147c

Nivestym

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-08-12
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE NIVESTYM is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT). ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia. ( 1.5 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NIVESTYM is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NIVESTYM is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NIVESTYM is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see Clinical Studies (14.3) ]. 1.4 Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy NIVESTYM is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [see Clinical Studies (14.4) ] . 1.5 Patients with Severe Chronic Neutropenia NIVESTYM is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia [see Clinical Studies (14.5) ] .

Full extracted label fields

application numbers

BLA761080

boxed warning exact

brand names

Nivestym

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

generic names

FILGRASTIM-AAFI

e73179c2-1306-443c-a5ed-d2748e96147c

indications and usage exact

1 INDICATIONS AND USAGE NIVESTYM is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT). ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia. ( 1.5 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NIVESTYM is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NIVESTYM is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NIVESTYM is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see Clinical Studies (14.3) ]. 1.4 Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy NIVESTYM is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [see Clinical Studies (14.4) ] . 1.5 Patients with Severe Chronic Neutropenia NIVESTYM is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia [see Clinical Studies (14.5) ] .

indications and usage tables exact

is original packager

true

manufacturer names

Pfizer Laboratories Div Pfizer Inc

matched search terms

cancer
leukemia

package ndcs

0069-0293-01
0069-0293-10
0069-0294-01
0069-0294-10
0069-0291-01
0069-0291-10
0069-0292-01
0069-0292-10

product ndcs

0069-0291
0069-0293
0069-0294
0069-0292

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS
INTRAVENOUS

rxcuis

2057200
2057205
2057209
2057212
2057215
2057216
2057218
2057219

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA761080

brand names

Nivestym

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 274
end exclusive: true
exact text: 1 INDICATIONS AND USAGE NIVESTYM is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incide
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 0

current approval status

not_reconciled

duplicate text group

dup-dbaed9e5f676b6915aa4

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-b4e966a9530c310912ea

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

end: 71
end exclusive: true
exact text: is a leukocyte growth factor indicated
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 33

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 74
end exclusive: true
exact text: 1 INDICATIONS AND USAGE NIVESTYM is a leukocyte growth factor indicated to
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

BLA761080

brand names

Nivestym

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 511
end exclusive: true
exact text: 1 INDICATIONS AND USAGE NIVESTYM is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). ( 1.2 ) • Reduce
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 0

current approval status

not_reconciled

duplicate text group

dup-5bc590b57ec1fb4805f4

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-da054860ecdb72f39d23

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 311
end exclusive: true
exact text: • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 75

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

BLA761080

brand names

Nivestym

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 519
end exclusive: true
exact text: ‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). ( 1.2 ) • Reduce the dur
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 112

current approval status

not_reconciled

duplicate text group

dup-1193cc77ddd5b7e17fa2

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-30d9724ae38d334cd3f4

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 319
end exclusive: true
exact text: ( 1.1 )
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 312

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

BLA761080

brand names

Nivestym

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 694
end exclusive: true
exact text: ifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy follo
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 120

current approval status

not_reconciled

duplicate text group

dup-4ab775151bf9fc876c10

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-9a16f0e090b47e626c6e

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 494
end exclusive: true
exact text: • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML).
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 320

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

BLA761080

brand names

Nivestym

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 702
end exclusive: true
exact text: enia with fever. ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by b
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 295

current approval status

not_reconciled

duplicate text group

dup-698b1934b97f3cf8061c

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-c81e4d2f9da1003bfa55

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 502
end exclusive: true
exact text: ( 1.2 )
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 495

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

BLA761080

brand names

Nivestym

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 935
end exclusive: true
exact text: h fever. ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT). ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 303

current approval status

not_reconciled

duplicate text group

dup-223f9a11cc94607ee5c7

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-4887d05f0ce6ba20db35

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 735
end exclusive: true
exact text: • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT).
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 503

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

BLA761080

brand names

Nivestym

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 943
end exclusive: true
exact text: nia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT). ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fe
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 536

current approval status

not_reconciled

duplicate text group

dup-b841e09a97d2cdc47085

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-3aedd0368d3a7f3ff988

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 743
end exclusive: true
exact text: ( 1.3 )
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 736

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

BLA761080

brand names

Nivestym

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1055
end exclusive: true
exact text: neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT). ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 544

current approval status

not_reconciled

duplicate text group

dup-35a1322f2ed82687b91c

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-d86cd8d7dc9a9823418d

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 855
end exclusive: true
exact text: • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 744

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

BLA761080

brand names

Nivestym

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1063
end exclusive: true
exact text: going myeloablative chemotherapy followed by bone marrow transplantation (BMT). ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiop
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 656

current approval status

not_reconciled

duplicate text group

dup-2bedacb4e4df20c6c4ce

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-765869d8e05b30f4a518

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 863
end exclusive: true
exact text: ( 1.4 )
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 856

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

BLA761080

brand names

Nivestym

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1281
end exclusive: true
exact text: eloablative chemotherapy followed by bone marrow transplantation (BMT). ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia. ( 1.5 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NIVESTYM is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloi
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 664

current approval status

not_reconciled

duplicate text group

dup-98da9fa59952465fcec9

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-c87ded5d6aa8b82cc5c6

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1081
end exclusive: true
exact text: • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia.
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 864

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

BLA761080

brand names

Nivestym

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1289
end exclusive: true
exact text: ence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia. ( 1.5 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NIVESTYM is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malign
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 882

current approval status

not_reconciled

duplicate text group

dup-0fa57cbbec2c3283d281

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-502384060625f114ab82

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1089
end exclusive: true
exact text: ( 1.5 )
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 1082

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · positive indication candidate

application numbers

BLA761080

brand names

Nivestym

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1646
end exclusive: true
exact text: duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia. ( 1.5 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NIVESTYM is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NIVESTYM is indicated for reducing the time to neutrophil recovery and the duration of fever, following indu
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 890

current approval status

not_reconciled

duplicate text group

dup-562f54cde4b9576e9226

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-82a0545333b60ff9749a

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

end: 1176
end exclusive: true
exact text: is indicated
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 1164

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1446
end exclusive: true
exact text: 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NIVESTYM is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] .
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 1090

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 13 · positive indication candidate

application numbers

BLA761080

brand names

Nivestym

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1970
end exclusive: true
exact text: openia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NIVESTYM is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NIVESTYM is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in pa
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 1247

current approval status

not_reconciled

duplicate text group

dup-d99ea0ae1e7ced99a830

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-96a988e24681ac7e1d14

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

end: 1559
end exclusive: true
exact text: is indicated
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 1547

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1770
end exclusive: true
exact text: 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NIVESTYM is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] .
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 1447

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 14 · positive indication candidate

application numbers

BLA761080

brand names

Nivestym

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2315
end exclusive: true
exact text: g the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2) ] . 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NIVESTYM is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see Clinical Studies (14.3) ]. 1.4 Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy NIVESTYM is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 1571

current approval status

not_reconciled

duplicate text group

dup-6bcdd392113beb91d95c

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-b780d23f9ac774002fb9

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

end: 1856
end exclusive: true
exact text: is indicated
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 1844

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2115
end exclusive: true
exact text: 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation NIVESTYM is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see Clinical Studies (14.3) ].
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 1771

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 15 · positive indication candidate

application numbers

BLA761080

brand names

Nivestym

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2585
end exclusive: true
exact text: ed clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see Clinical Studies (14.3) ]. 1.4 Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy NIVESTYM is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [see Clinical Studies (14.4) ] . 1.5 Patients with Severe Chronic Neutropenia NIVESTYM is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal u
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 1916

current approval status

not_reconciled

duplicate text group

dup-d03beb397b0dbae021bd

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-156aff1e73c54c6df0c1

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

end: 2228
end exclusive: true
exact text: is indicated
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 2216

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2385
end exclusive: true
exact text: 1.4 Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy NIVESTYM is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [see Clinical Studies (14.4) ] .
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 2116

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 16 · positive indication candidate

application numbers

BLA761080

brand names

Nivestym

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2723
end exclusive: true
exact text: llection and Therapy NIVESTYM is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [see Clinical Studies (14.4) ] . 1.5 Patients with Severe Chronic Neutropenia NIVESTYM is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia [see Clinical Studies (14.5) ] .
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 2186

current approval status

not_reconciled

duplicate text group

dup-d48d4d4dbba6d4c0b66c

extraction review status

automated_candidate_pending_source_review

generic names

FILGRASTIM-AAFI

ind-span-c5ea5c83d55266489962

label id

e73179c2-1306-443c-a5ed-d2748e96147c

positive predicate support span

end: 2452
end exclusive: true
exact text: is indicated
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 2440

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2723
end exclusive: true
exact text: 1.5 Patients with Severe Chronic Neutropenia NIVESTYM is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia [see Clinical Studies (14.5) ] .
label id: e73179c2-1306-443c-a5ed-d2748e96147c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 6175e04308d49f6674bb6dcd562b23c3d29a279ece5453c341b16b1218658bab
start: 2386

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e73179c2-1306-443c-a5ed-d2748e96147c%22

spl effective date

2025-08-12

spl set id

d23ab39c-b6ec-41cf-a529-9dd2852c9d9a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice